Daniel E. Geffken
2022 - Sevion Therapeutics
In 2022, Daniel E. Geffken earned a total compensation of $64K as Interim Chief Financial Officer at Sevion Therapeutics, a 51% decrease compared to previous year.
Compensation breakdown
Other | $63,960 |
---|---|
Total | $63,960 |
Geffken received $64K in other compensation, accounting for 100% of the total pay in 2022.
Rankings
In 2022, Daniel E. Geffken's compensation ranked 5,661st out of 5,756 executives tracked by ExecPay. In other words, Geffken earned more than 1.7% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,661 | 2nd |
Manufacturing | 3,090 | 1st |
Chemicals And Allied Products | 1,406 | 1st |
Drugs | 1,308 | 1st |
Biological Products, Except Diagnostic Substances | 290 | 0th |
Geffken's colleagues
We found two more compensation records of executives who worked with Daniel E. Geffken at Sevion Therapeutics in 2022.